Sai Parenterals inches up on inking pact to acquire majority stake in Bion Therapeutics India
Sai Parenteral's is currently trading at Rs. 498.65, up by 0.20 points or 0.06% from its previous closing of Rs. 498.45 on the BSE.
The scrip opened at Rs. 498.45 and has touched a high and low of Rs. 504.90 and Rs. 493.00 respectively. So far 5341 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 5 has touched a 52 week high of Rs. 705.00 on 02-Jul-2026 and a 52 week low of Rs. 400.00 on 02-Apr-2026.
Last one week high and low of the scrip stood at Rs. 525.00 and Rs. 490.25 respectively. The current market cap of the company is Rs. 2217.58 crore.
The promoters holding in the company stood at 51.16%, while Institutions and Non-Institutions held 10.69% and 38.15% respectively.
Sai Parenterals, through its wholly owned subsidiary SP Analytics, has signed a definitive agreement to acquire a majority stake in Bion Therapeutics India (Bion), a Hyderabad-based branded formulations prescription business company. Bion will become a step-down subsidiary of Sai Parenterals on completion of the deal, which is expected before the end of this month. The transaction will be an all-cash deal.
Bion Therapeutics, founded in 2005, is a prescription based branded formulation company that builds products, manufactured with accredited contract manufacturing partners. Bion’s extensive infrastructure will provide Sai Parenterals with immediate access to a broader market, enhancing its competitive position in the domestic pharmaceutical landscape. With recent acquisition of Sai Prathyak Laboratories, in-house R&D centre with a portfolio of 174 molecules and 285 SKUs, Bion creates value addition and provides a commercial platform for Sai Parenterals with an established field team to take it to the prescription market. Bion’s existing management team will continue to spearhead the business following the completion of acquisition, retaining the doctor relationships and market knowledge on which the franchise rests.
